Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology
®
Neoadjuvant HER2+
Bone Metastases
Brain Cancer
Business Management
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Genitourinary Cancers
Head & Neck Cancers
Hematologic Oncology
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Non-Hodgkin Lymphoma
Oncology Nursing News
Patient Resources
Sarcomas/TGCT
Special Reports in Personalized Cancer Care
Supportive Care
Online CME
Interactive Publications
SELECT A TOPIC
CURRENT VIEW
All Specialties
▲
Education ▲
Education ▼
Register
|
Login
Conference Coverage
Videos
NewsNetwork
OncLive
®
TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
Giants of Cancer Care
ISGIO
Webinars
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology
®
Neoadjuvant HER2+
More >>
OncLive TV: A. Daniel Pinheiro, MD
<< Back to Our Featured Experts
Dr. Pinheiro on Determinants of Cost in the Treatment of T1-T3 Oropharynx Cancer
Oncology Specialists
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
S. Yousuf Zafar, MD
Gregory Zagaja, MD
Jasmine Zain, MD
Jasmine M. Zain, MD
Tal Zaks, MD, PhD
Mark M. Zalupski, MD
Dmitriy Zamarin, MD, PhD
Dan Zandberg, MD
Hassane M. Zarour, MD
Kimberly J. Van Zee, MD
Kimberly Van Zee, MD
Andrew D. Zelenetz, MD, PhD
Tian Zhang, MD
Jingsong Zhang, MD, PhD
Andrew Zhu, MD, PhD
Viola W. Zhu, MD, PhD
You-cai Zhu, MD, PhD
Matthew R. Zibelman, MD
Oliver Zill
Ari Zimran, MD
Jeffrey Zonder, MD
Yu (Amy) Zong
Dieter Zopf
Jo Anne Zujewski, MD
Javier Zulueta, MD
OncLive News Network On Location: ASH 2019 Day 3
Trending Now
Palbociclib Real-World Results Indicate OS Benefit in Frontline HR+/HER2- Breast Cancer
Daratumumab Boosts Outcomes in Transplant-Eligible Myeloma
Adjuvant Pertuzumab Regimen Shows Modest OS Benefit in HER2+ Early Breast Cancer
Tucatinib Boosts Survival in HER2+ Breast Cancer, FDA Submission Imminent
Publications
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
x
Subscribe